MedTrace Logo

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

NCT01014962 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-06-20

No results posted yet for this study

Summary

The purpose of this study is to determine an upper dose of albaconzole to be administered in a Thorough QTc study.

Conditions

  • Onychomycosis

Interventions

DRUG

Albaconozole

Albaconozole 400 mg oral once daily for 5 days

DRUG

Placebo

Placebo oral once daily for 5 days

DRUG

Albaconozole

Albaconozole 400 mg every 12 hours for 5 days

DRUG

Placebo

Placebo oral every 12 hours for 5 days

DRUG

Albaconozole

Albaconozole 400 mg oral every 8 hours for 5 days

DRUG

Placebo

Placebo oral every 8 hours for 5 days

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Stiefel, a GSK Company

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-24
Primary Completion
2009-12-04
Completion
2009-12-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01014962 on ClinicalTrials.gov